Oruka Therapeutics Inc. announced positive interim data from its Phase 1 trial of ORKA-002, a novel biologic candidate for chronic skin diseases, including plaque psoriasis and hidradenitis suppurativa. The Phase 1 trial, which enrolled 24 healthy adult participants, demonstrated that ORKA-002 has a half-life of 75-80 days, supporting potential for twice-yearly dosing in psoriasis and quarterly dosing in hidradenitis suppurativa. The drug was well tolerated at all tested dose levels, with no severe or serious adverse events reported. Additional data from the trial will be presented at an upcoming medical meeting. Oruka Therapeutics also announced that Phase 2 studies for ORKA-002 are expected to begin in the first half of 2026 for psoriasis and in the second half of 2026 for hidradenitis suppurativa. Additionally, the first patients were dosed in December 2025 in the EVERLAST-B Phase 2b trial of ORKA-001, with data expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623520-en) on January 12, 2026, and is solely responsible for the information contained therein.